Sleep pill may quiet Brain's cannabis cravings
NCT ID NCT06584942
First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 2 times
Summary
This study tests whether suvorexant (Belsomra), a sleep medication, can lower brain activity linked to cannabis cravings. Twenty adults who use cannabis daily will take the drug for 14 days and undergo brain scans before and after. The goal is to see if the medication reduces the brain's response to cannabis-related cues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
20 people
The number who actually took part.
- Started
-
Mar 2025
- Finished
-
Jun 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 60 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 18-60 years, inclusive * Use cannabis daily or near daily and have been using cannabis consistently for at least the past year, by self-report * Meet criteria for cannabis use disorder (CUDIT-R scores greater than or equal to 8) * Female participants of childbearing potential must have a negative pregnancy test at the enrollment visit * Be able to read, speak, and understand the English language. English can be a second language, provided that the subject understands all the questions used in the assessment measures. * Access to a mobile device to complete daily surveys Exclusion Criteria: * Participants cannot have an acutely unstable medical or psychiatric illness * Medications with the potential to depress CNS function will be assessed by the PI or study physician and participants will be excluded as necessary * Participants cannot have a history of major head trauma resulting in cognitive impairment, seizure, or other neurological disorders * Presence of metallic foreign bodies such as cardiac pacemakers, perfusion pumps, aneurysm clips, metallic tattoos anywhere on the body, tattoos near the eye * Individuals with severe hepatic impairment will be excluded * Participants cannot be obese as determined by a Body Mass Index (BMI) or greater than 35 * Participants cannot be using a CYP3A inhibitor/inducer (metabolism by CYP3A is the major elimination pathway for suvorexant) * Participants cannot have a current cardiac disorder such as palpitations, tachycardia, and/or the use of the cardiac medication Digoxin * Participants cannot have narcolepsy * Participants cannot self-report complex sleep behaviors such as sleep driving, preparing and eating food, or making phone calls * Participants cannot be actively suicidal (current suicidal ideation with specific plan or intent) and/or report a suicide attempt or psychiatric hospitalization in the past year * Participants cannot have a current substance use disorder based on a DSM-V diagnosis and MINI Interview for Substance Use Disorders other than nicotine and cannabis and cannot meet criteria for moderate or severe alcohol use disorder * Pregnancy or breastfeeding: a negative pregnancy test is required at the enrollment visit * In the opinion of the investigators, not able to complete study procedures or safely participate in the study
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cannabis use disorder are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Center for Addiction Medicine, Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a website help people cut back on cannabis?
- Brain scans probe why cannabis hits men and women differently
- Can rewards and remote coaching help people cut back on cannabis?
- Can a phone app curb cannabis use in early psychosis?
- Can a sleep pill curb cannabis addiction?
- Pharmacies vs. street: does regulated cannabis improve health?